Literature DB >> 18332205

Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection.

Ying Wu1, Joshua S Woodworth, Daniel S Shin, Sheldon Morris, Samuel M Behar.   

Abstract

The 10-kDa culture filtrate protein (CFP-10) and 6-kDa early secretory antigen of T cells (ESAT-6) are secreted in abundance by Mycobacterium tuberculosis and are frequently recognized by T cells from infected people. The genes encoding these proteins have been deleted from the genome of the vaccine strain Mycobacterium bovis bacillus Calmette-Guérin (BCG), and it is hypothesized that these proteins are important targets of protective immunity. Indeed, vaccination with ESAT-6 elicits protective CD4+ T cells in C57BL/6 mice. We have previously shown that M. tuberculosis infection of C3H mice elicits CFP-10-specific CD8+ and CD4+ T cells. Here we demonstrate that immunization with a CFP-10 DNA vaccine stimulates a specific T-cell response only to the H-2K(k)-restricted epitope CFP-10(32-39). These CFP-10(32-39)-specific CD8+ cells undergo a rapid expansion and accumulate in the lung following challenge of immunized mice with aerosolized M. tuberculosis. Protective immunity is induced by CFP-10 DNA vaccination as measured by a CFU reduction in the lung and spleen 4 and 8 weeks after challenge with M. tuberculosis. These data demonstrate that CFP-10 is a protective antigen and that CFP-10(32-39)-specific CD8+ T cells elicited by vaccination are sufficient to mediate protection against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332205      PMCID: PMC2346695          DOI: 10.1128/IAI.00024-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis.

Authors:  Joseph Hinchey; Sunhee Lee; Bo Y Jeon; Randall J Basaraba; Manjunatha M Venkataswamy; Bing Chen; John Chan; Miriam Braunstein; Ian M Orme; Steven C Derrick; Sheldon L Morris; William R Jacobs; Steven A Porcelli
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.

Authors:  H McShane; R Brookes; S C Gilbert; A V Hill
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Authors:  Giovanni Delogu; Amy Li; Charlene Repique; Frank Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

4.  The immunogenicity of single and combination DNA vaccines against tuberculosis.

Authors:  S Morris; C Kelley; A Howard; Z Li; F Collins
Journal:  Vaccine       Date:  2000-04-14       Impact factor: 3.641

5.  Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen.

Authors:  A W Olsen; P R Hansen; A Holm; P Andersen
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

6.  Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity.

Authors:  D M Lewinsohn; L Zhu; V J Madison; D C Dillon; S P Fling; S G Reed; K H Grabstein; M R Alderson
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

7.  Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.

Authors:  Nilu P Goonetilleke; Helen McShane; Carolyn M Hannan; Richard J Anderson; Roger H Brookes; Adrian V S Hill
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

8.  Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A.

Authors:  Joanna R Kirman; Tara Turon; Hua Su; Amy Li; Carl Kraus; John M Polo; John Belisle; Sheldon Morris; Robert A Seder
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Authors:  Alexander S Pym; Priscille Brodin; Laleh Majlessi; Roland Brosch; Caroline Demangel; Ann Williams; Karen E Griffiths; Gilles Marchal; Claude Leclerc; Stewart T Cole
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

10.  Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity.

Authors:  Alissa A Chackerian; Jennifer M Alt; Thushara V Perera; Christopher C Dascher; Samuel M Behar
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more
  23 in total

1.  Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Authors:  Xindong Teng; Maopeng Tian; Jianrong Li; Songwei Tan; Xuefeng Yuan; Qi Yu; Yukai Jing; Zhiping Zhang; Tingting Yue; Lei Zhou; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

3.  CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection.

Authors:  Tyler D Bold; Joel D Ernst
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

Review 4.  Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.

Authors:  Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman
Journal:  Semin Immunol       Date:  2014-10-11       Impact factor: 11.130

5.  Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination.

Authors:  Joshua S Woodworth; Daniel Shin; Mattijs Volman; Cláudio Nunes-Alves; Sarah M Fortune; Samuel M Behar
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

6.  Mycobacterium tuberculosis-Induced Bronchoalveolar Lavage Gene Expression Signature in Latent Tuberculosis Infection Is Dominated by Pleiotropic Effects of CD4+ T Cell-Dependent IFN-γ Production despite the Presence of Polyfunctional T Cells within the Airways.

Authors:  Jessica Jarvela; Michelle Moyer; Patrick Leahy; Tracey Bonfield; David Fletcher; Wambura N Mkono; Htin Aung; David H Canaday; Jean-Eudes Dazard; Richard F Silver
Journal:  J Immunol       Date:  2019-09-20       Impact factor: 5.422

7.  Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo.

Authors:  Joshua S Woodworth; Ying Wu; Samuel M Behar
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 8.  T cells in mycobacterial infection and disease.

Authors:  Andrea M Cooper
Journal:  Curr Opin Immunol       Date:  2009-07-29       Impact factor: 7.486

9.  A critical role for CD8 T cells in a nonhuman primate model of tuberculosis.

Authors:  Crystal Y Chen; Dan Huang; Richard C Wang; Ling Shen; Gucheng Zeng; Shuyun Yao; Yun Shen; Lisa Halliday; Jeff Fortman; Milton McAllister; Jim Estep; Robert Hunt; Daphne Vasconcelos; George Du; Steven A Porcelli; Michelle H Larsen; William R Jacobs; Barton F Haynes; Norman L Letvin; Zheng W Chen
Journal:  PLoS Pathog       Date:  2009-04-17       Impact factor: 6.823

10.  CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

Authors:  Tara Elvang; Jan P Christensen; Rolf Billeskov; Truc Thi Kim Thanh Hoang; Peter Holst; Allan Randrup Thomsen; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.